The guidance, Nonproprietary Naming of Biologic Products, would designate specific and separate, nonproprietary titles for originator biologic products, related biological products, and biosimilar products. The ACR commends the FDA's proposal to require distinctive names for biosimilar medications and first biologics, said Douglas White, MD, Chair of the ACR's Committee on Rheumatologic Treatment. Distinctive names permits better transparency in substitution and notification, rendering it clear to all or any parties involved – pharmacists, providers and patients – which drug the patient is receiving. Related StoriesNo progression in joint harm in 84 percent of psoriatic arthritis patientsHSS researchers help identify lupus sufferers at increased threat of problem pregnanciesResistance weight training reduces pain, boosts function in people who have hand OAThe ACR previously released a position statement calling on the FDA to enforce distinct names for biosimilars, and offers spoken with FDA officials and submitted comment letters expressing its worries for patient protection in instances where biosimilars are substituted without proper patient and doctor notification.announced today that, pursuant to the last authorization of its board of directors, ARC Healthcare intends to keep payment of regular distributions at an annualized rate of $0.68 per share. Pending the Effective Period as described in the merger agreement entered into, by and among, the ongoing company and Ventas, Inc. Of June 1 and dated as, 2014, the business intends to continue paying distributions on a monthly basis to stockholders of record at the close of business on the 8th day of the relevant month, payable on the 15th day of the applicable month, in each case, unless such date is a nonbusiness day.